

MONDAY, May 31, 2010

Opening ceremony 8.30-10.15

Inaugural lecture: Prof. Mc Farland (*USA*)

The importance of clinical trials in unraveling the mysteries of multiple sclerosis

Chopin Piano Concert

10.15–10.45 Coffee break

10.45-13.30 Session I – Multiple Sclerosis

(Chair: P. Hartung, J. Losy)

P. Hartung (*Germany*)

Recent advances in monoclonal antibodies therapy in MS

H. Offner (*USA*)

RTL Therapy for Multiple Sclerosis Phase 1 Clinical Study

J. Losy (*Poland*)

Oral therapies for MS

R. Milo (*Israel*)

Combination therapy for MS

13.30–14.30 Lunch

14.30–16.00 Baxter satellite session – IVIG and autoimmune neurological disorders

(Chair: J. Kotowicz)

J. Kotowicz (*Poland*)

Introduction

L. Van den Berg (*Netherlands*)

Clinical diagnosis of multifocal motor neuropathy

J. Jakobsen (*Denmark*)

Clinical diagnosis and treatment of CIDP

J. Kotowicz (*Poland*)

The role of IVIG in GBS treatment

16.15–17.45 Session II – Myopathies

(Chair: M. Dimachkie, J. Zaremba)

M. Dimachkie (*USA*)

Idiopathic inflammatory myopathies

Z. Illes (*Hungary*)

Clinical and biological heterogeneity of autoimmune Myasthenia Gravis

T. Holmoy (*Norway*)

Stiff person syndrome

20.30 Dinner in Marine Museum**TUESDAY, June 1, 2010****09.00–10.30 Session III – Autoimmune neuropathies**

(Chair: M.P. Collins, A. Członkowska)

M.P. Collins (*USA*)

Vasculitic neuropathy

H. Lehmann (*Germany*)

Plasmapheresis and intravenous immunoglobulins treatment in autoimmune neuropathies

J. Winer (*UK*)

Guillain Barre Syndrome and its variants

10.30–12.00 Merc-Serono satellite session – Oral cladribine – new hope for MS patients

(Chair: J. Losy)

P. Grieb (*Poland*)

Development of Cladribine: the road to oral therapy for Multiple sclerosis

J. Losy (*Poland*)

Cladribine oral therapy in multiple sclerosis – Results of CLARITY Study

12.00–13.00 Lunch

13.00–16.30 Session IV – Immune system and chosen neurological disorders

(Chair: R. Weissert, R. Furlan)

R. Weissert (*Germany*)

Progressive multifocal leukoencephalopathy

A. Czlonkowska (*Poland*)

Inflammation and gliosis in neurological diseases – clinical implications

K.P. Wandinger (*Germany*)

Anti-NMDA receptor encephalitis

14.30–15.00 Coffee break

M. Wender (*Poland*)

ADEM

R. Furlan (*Italy*)

Neuromyelitis optica

A. Dressel (*Germany*)

Ischemic stroke. Why neuroimmunologists should care

Concluding remarks: J. Losy

POSTERS

P01 The role of β -estradiol on the expression of cytokines in astrocytes

Piroozzi A., Mohsenzadeh M.

P02 Antibodies in neurological diseases of children as predictive values for estimation level of severity morbidity

Bajraktarevic A., Eminagic S., Rovcanin A., Omerovic M., Ceman Saric J., Musabegovic J., Sladic H., Vranic B., Hamamdzic M., Djurdjevic Djulepa A.

P03 Association of Proliferator-Activated Receptor-Gamma (PPAR- γ) PRO12Ala Polymorphism with susceptibility to Multiple Sclerosis (MS)

Tabvili S., Khoram-Rooz S., Khalesi M., Kamali-Sarvestani E.

P04 Relationship among IgG oligoclonal bands number, intrathecal IgG production and some biochemical parameters in multiple sclerosis patients

Ondrkalová M., Kalnovičová T., Turčáni P.

P05 Plasma uric acid levels in patients with Multiple sclerosis

Kuračka L., Kalnovičová T., Turčáni P.

P06 Purine nucleotides degradation products as possibly marker of tissue destruction in Multiple sclerosis

Kuračka L., Volaříková V., Kalnovičová T., Turčáni P.

P07 Cytokine regulation of the immunity in cerebral ischemia of the patients with severe combined trauma

Mazilina A., Rosanov V., Bolotnikov A., Dzirikova N., Bondarenko A.

- P08 Fas/CD95 – indirect apoptosis in mechanism of brain dysfunction in patients with severe combined trauma
Mazilina A., Rosanov V., Bolotnikov A., Dzirikova N., Bondarenko A.
- P09 Proliferative activity of tumours of CNS
Shah T., Yar M., Davichenka V.P., Melchenka E.V.
- P10 Antiphospholipid antibodies in patients with multiple sclerosis – immunological and clinical implications
Szymyrka-Kaczmarek M., Pokryszko-Dragan A., Gruszka E., Bilińska M., Podemski R., Pawlik B., Korman L., Grzebyk K., Wiland P.
- P11 Poly(ADP-ribose) polymerase (PARP) is activated in multiple sclerosis pattern III lesions and its inhibition prevents experimental demyelination and oligodendrocyte death
Veto S., Acs P., Bauer J., Lassmann H., Berente Z., Sumegi B., Komoly S., Gallyas Jr F., Illes Z.
- P12 Effect of Vitamin D on Epstein-Barr (EBV)-specific CD8+ T cells in patients with early multiple sclerosis (MS)
Lysandropoulos A., Jaquiéry E., Zekeidou A., Jilek S., Canales M., Pantaleo G., Schlupe M., Du Pasquier R.
- P13 Chemokines CCL2, CCL3, CXCL5, and CXCL5 in haemorrhagic stroke
Zaremba J., Losy J.
- P14 The effect of Betaferon and Avonex therapy on the serum concentration of the inflammatory factors in patients with multiple sclerosis
Lubina-Dąbrowska N., Chalimoniuk M., Maciągowska M., Stępień A.
- P15 The effects of interferon β on inflammatory factors in brain cortex of experimental autoimmune encephalomyelitis
Lubina-Dąbrowska N., Sulkowski G., Dąbrowska-Bouta B., Langfort J., Stępień A., Chalimoniuk M.
- P16 Reaction time test is a useful marker of composite cognitive deficit in multiple sclerosis patients
Kalinowska-Lyszczarz A., Pawlak M.A., Losy J.
- P17 In vitro effects of Interferon- β 1b on cytokine patterns of CD4+ and CD8+ T-cell derived from PPMS and RRMS patients
Skrzipek S., Rosenberg S., Peters S., Vogelgesang A., Bröker B., Dressel A.
- P18 Associations of TNFAIP3 rs2230926 Polymorphisms with myasthenia gravis
Xie Y.-C., Zhao Y., Sun L., Li H.-F., Zhu X.-Q., Jiang B., Wang S.-H., Wang S.-X., Wang D.-X., Yang Z.
- P19 The Warsaw Registry of Myasthenia Gravis Patients
Szczudlik P., Lipowska M., Szyluk B., Rynievicz B., Kostera-Pruszczyk A., Kwiecinski H.
- P20 CCR5 and its ligands in the development of autoimmune inflammation in the CNS
Jaczak I., Pietruczuk M., Glabinski A.
- P21 Immunomodulatory effects of IFN beta and lovastatin on immunophenotype of monocyte-derived dendritic cells and secretion chemokines in multiple sclerosis patients
Pocińska K., Gruszczak A., Stelmasiak Z., Bartosik-Psujek H.
- P22 Analysis of 103 Hungarian patients with neuromyelitis optica (NMO) spectrum disorders
Kozségi E., Banati M., Bors L., Hemmer B., Berthele A., Molnar T., Csepány T., Rozsa C., Simó M., Jakab G., Komoly S., Illes Z.
- P23 The clinical value of high-sensitivity C-reactive protein (hsCRP) and serum amyloid A (SAA) in acute phase of ischemic stroke
Palasik W., Tadeusiak W., Fiszler U.